AR062545A1 - Formulaciones estables de quinolinonas - Google Patents
Formulaciones estables de quinolinonasInfo
- Publication number
- AR062545A1 AR062545A1 ARP060105279A ARP060105279A AR062545A1 AR 062545 A1 AR062545 A1 AR 062545A1 AR P060105279 A ARP060105279 A AR P060105279A AR P060105279 A ARP060105279 A AR P060105279A AR 062545 A1 AR062545 A1 AR 062545A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- mixture
- tautomer
- pharmaceutical
- salt
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- 229930185107 quinolinone Natural products 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 2
- 229920002472 Starch Polymers 0.000 abstract 2
- 239000002775 capsule Substances 0.000 abstract 2
- 239000001913 cellulose Substances 0.000 abstract 2
- 229920002678 cellulose Polymers 0.000 abstract 2
- 229960000913 crospovidone Drugs 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 239000008101 lactose Substances 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 2
- 229940032147 starch Drugs 0.000 abstract 2
- 235000019698 starch Nutrition 0.000 abstract 2
- 239000008107 starch Substances 0.000 abstract 2
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229960001375 lactose Drugs 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 238000009512 pharmaceutical packaging Methods 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 235000012239 silicon dioxide Nutrition 0.000 abstract 1
- 229940079832 sodium starch glycolate Drugs 0.000 abstract 1
- 229920003109 sodium starch glycolate Polymers 0.000 abstract 1
- 239000008109 sodium starch glycolate Substances 0.000 abstract 1
- 239000000454 talc Substances 0.000 abstract 1
- 229910052623 talc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una formulacion farmacéutica que comprende un compuesto de formula (1), un tautomero del compuesto, una sal del compuesto, una sal del tautomero o una mezcla de los mismos, al menos un ingrediente seleccionado del grupo formado por (i) celulosa; (ji) dioxido de silicona; (iii) estearato de magnesio; y (iv) un ingrediente seleccionado entre crospovidona, almidon o lactosa. Reivindicacion 31: Un método para producir una formulacion farmacéutica, que comprende: (a) combinar una primera mezcla para proveer una primera mezcla combinada, en donde la primera mezcla comprende: (i) un compuesto de formula 1, un tautomero del compuesto, una sal aceptable para uso farmacéutico del compuesto, una sal aceptable para uso farmacéutico del tautomero, o una mezcla de los mismos, y (ii) al menos un componente que se selecciona del grupo que consiste en celulosa; lactosa, almidon, o una mezcla de los mismos; povidona; dioxido de silicio o talco; un lubricante aceptable para uso farmacéutico; y un componente seleccionado entre crospovidona, croscarmelosa de sodio; o glicolato de almidon sodico. Reivindicacion 58: Un recipiente de empaquetamiento farmacéutico, que comprende: un recipiente de almacenamiento que comprende dos o más cápsulas o tabletas, en donde las cápsulas o tabletas comprenden la formulacion farmacéutica de cualquiera de las reivindicaciones 1-30. Reivindicacion 68: Un método para tratar el cáncer y/o inhibir la angiogénesis en un sujeto, que comprende: administrar la formulacion de acuerdo a cualquiera de las reivindicaciones 1-30 al sujeto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74057705P | 2005-11-29 | 2005-11-29 | |
| US74131705P | 2005-12-01 | 2005-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062545A1 true AR062545A1 (es) | 2008-11-19 |
Family
ID=38024178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105279A AR062545A1 (es) | 2005-11-29 | 2006-11-29 | Formulaciones estables de quinolinonas |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20080293738A1 (es) |
| EP (2) | EP2772257A1 (es) |
| JP (1) | JP2009517481A (es) |
| KR (1) | KR20080074143A (es) |
| CN (1) | CN102670530A (es) |
| AR (1) | AR062545A1 (es) |
| AU (1) | AU2006320591B2 (es) |
| BR (1) | BRPI0619370A2 (es) |
| CA (1) | CA2627544C (es) |
| CL (1) | CL2010000387A1 (es) |
| EC (1) | ECSP088467A (es) |
| ES (1) | ES2467162T3 (es) |
| IL (1) | IL190865A0 (es) |
| MA (1) | MA29969B1 (es) |
| MY (1) | MY148529A (es) |
| NO (1) | NO20082938L (es) |
| NZ (1) | NZ567550A (es) |
| PE (1) | PE20070760A1 (es) |
| PL (1) | PL1957074T3 (es) |
| PT (1) | PT1957074E (es) |
| RU (1) | RU2433826C2 (es) |
| TW (1) | TW200730176A (es) |
| WO (1) | WO2007064719A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR070924A1 (es) * | 2008-03-19 | 2010-05-12 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona |
| MX2010012814A (es) | 2008-05-23 | 2010-12-20 | Amira Pharmaceuticals Inc | Inhibidor de proteina activadora de 5-lipoxigenasa. |
| KR20110031485A (ko) * | 2008-07-03 | 2011-03-28 | 노파르티스 아게 | 용융 과립화 방법 |
| AR081776A1 (es) * | 2010-06-30 | 2012-10-17 | Novartis Ag | Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion |
| WO2013063003A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
| CN104093402A (zh) | 2012-01-31 | 2014-10-08 | 诺华股份有限公司 | Rtk抑制剂与抗雌激素的组合及其治疗癌症的应用 |
| JP2015522070A (ja) | 2012-07-11 | 2015-08-03 | ノバルティス アーゲー | 消化管間質腫瘍を治療する方法 |
| WO2014058785A1 (en) | 2012-10-10 | 2014-04-17 | Novartis Ag | Combination therapy |
| TWI535784B (zh) | 2014-08-26 | 2016-06-01 | 財團法人工業技術研究院 | 剪切增稠配方、及包含其之複合材料 |
| CN113329734A (zh) * | 2018-12-06 | 2021-08-31 | 葛兰素史克知识产权开发有限公司 | 新颖的药物制剂 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3663606A (en) * | 1966-06-21 | 1972-05-16 | Mitsui Toatsu Chemicals | Organic imino-compounds |
| DE2363459A1 (de) | 1973-12-20 | 1975-06-26 | Basf Ag | Neue fluoreszierende chinolinverbindungen |
| US4119105A (en) | 1977-01-31 | 1978-10-10 | Olin Corporation | Air flow limiting filter |
| JPH0699497B2 (ja) | 1987-04-16 | 1994-12-07 | 富士写真フイルム株式会社 | 光重合性組成物 |
| GB9108547D0 (en) | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| JP3161780B2 (ja) | 1991-09-30 | 2001-04-25 | 東レ・ダウコーニング・シリコーン株式会社 | α，ω−ジヒドロキシフルオロアルキルメチルポリシロキサンの製造方法 |
| JP3142378B2 (ja) | 1992-06-22 | 2001-03-07 | ティーディーケイ株式会社 | 有機ｅｌ素子 |
| US5763441A (en) | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| JPH0743896A (ja) | 1993-07-28 | 1995-02-14 | Toyobo Co Ltd | 光重合性組成物 |
| JPH0829973A (ja) | 1994-07-11 | 1996-02-02 | Toyobo Co Ltd | 光重合性組成物 |
| JP3441246B2 (ja) | 1995-06-07 | 2003-08-25 | 富士写真フイルム株式会社 | 光重合性組成物 |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| US6010711A (en) * | 1996-01-26 | 2000-01-04 | University Of Rochester | Methods, articles and compositions for the pharmacologic inhibition of bone resorption with phosphodiesterase inhibitors |
| WO1997034876A1 (en) | 1996-03-15 | 1997-09-25 | Zeneca Limited | Cinnoline derivatives and use as medicine |
| DE19610723A1 (de) | 1996-03-19 | 1997-09-25 | Bayer Ag | Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen |
| BR9711805A (pt) | 1996-06-20 | 2002-01-15 | Regents The Univesity Of Texas | Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos |
| CN1252054C (zh) | 1996-09-25 | 2006-04-19 | 曾尼卡有限公司 | 抑制生长因子的作用的喹啉衍生物 |
| US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
| GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6294532B1 (en) | 1997-08-22 | 2001-09-25 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
| AU3850299A (en) | 1998-05-20 | 1999-12-06 | Kyowa Hakko Kogyo Co. Ltd. | Vegf activity inhibitors |
| US6138605A (en) | 1998-08-05 | 2000-10-31 | Seascape Systems Limited | Access and evacuation apparatus with articulated arm |
| DE19841985A1 (de) | 1998-09-03 | 2000-03-09 | Schering Ag | Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate |
| IL126953A0 (en) | 1998-11-08 | 1999-09-22 | Yeda Res & Dev | Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| EP1248642A4 (en) | 2000-01-18 | 2005-05-18 | Ludwig Inst Cancer Res | PEPTIDOMIMETIC INHIBITOR OF VEGF-D / VEGF-C / VEGF |
| EP1252308A2 (en) | 2000-01-19 | 2002-10-30 | Parkash S. Gill | Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides |
| GB0001930D0 (en) | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| PL202918B1 (pl) * | 2000-03-07 | 2009-08-31 | Rush Presbyterian St Luke | Przeciwbakteryjna i antykoncepcyjna kompozycja oraz jej zastosowanie |
| ATE448226T1 (de) | 2000-09-01 | 2009-11-15 | Novartis Vaccines & Diagnostic | Aza heterocyclische derivate und ihre therapeutische verwendung |
| US20030028018A1 (en) | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
| AP1666A (en) * | 2000-09-11 | 2006-09-29 | Chiron Corp | Quinolinone derivatives as tyrosine kinase inhibitors. |
| US6476068B1 (en) * | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
| US7825132B2 (en) * | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| CA2496164C (en) | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
| MXPA05004754A (es) | 2002-11-13 | 2005-08-02 | Chiron Corp | Metodos para tratar cancer y metodos relacionados. |
| EP1682529A4 (en) * | 2003-11-07 | 2010-06-30 | Novartis Vaccines & Diagnostic | PROCESS FOR SYNTHESIS OF CHINOLINONE COMPOUNDS |
| CN1960731B (zh) * | 2004-02-20 | 2011-12-07 | 诺华疫苗和诊断公司 | 调节炎性和转移过程的方法 |
| BRPI0613200A2 (pt) * | 2005-05-18 | 2012-01-03 | M & G Polimeri Italia Spa | composiÇço de poliÉster |
| EP1904480A2 (en) * | 2005-05-23 | 2008-04-02 | Novartis Pharma AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
-
2006
- 2006-11-29 EP EP14150490.2A patent/EP2772257A1/en not_active Withdrawn
- 2006-11-29 CN CN2012100464971A patent/CN102670530A/zh active Pending
- 2006-11-29 MY MYPI20081687A patent/MY148529A/en unknown
- 2006-11-29 EP EP06838590.5A patent/EP1957074B1/en active Active
- 2006-11-29 TW TW095144180A patent/TW200730176A/zh unknown
- 2006-11-29 PT PT68385905T patent/PT1957074E/pt unknown
- 2006-11-29 BR BRPI0619370-6A patent/BRPI0619370A2/pt not_active IP Right Cessation
- 2006-11-29 ES ES06838590.5T patent/ES2467162T3/es active Active
- 2006-11-29 PE PE2006001517A patent/PE20070760A1/es not_active Application Discontinuation
- 2006-11-29 US US12/094,806 patent/US20080293738A1/en not_active Abandoned
- 2006-11-29 PL PL06838590T patent/PL1957074T3/pl unknown
- 2006-11-29 AU AU2006320591A patent/AU2006320591B2/en not_active Ceased
- 2006-11-29 CA CA2627544A patent/CA2627544C/en not_active Expired - Fee Related
- 2006-11-29 NZ NZ567550A patent/NZ567550A/en not_active IP Right Cessation
- 2006-11-29 WO PCT/US2006/045711 patent/WO2007064719A2/en not_active Ceased
- 2006-11-29 KR KR1020087012826A patent/KR20080074143A/ko not_active Ceased
- 2006-11-29 JP JP2008543426A patent/JP2009517481A/ja active Pending
- 2006-11-29 AR ARP060105279A patent/AR062545A1/es unknown
- 2006-11-29 RU RU2008126384/15A patent/RU2433826C2/ru not_active IP Right Cessation
-
2008
- 2008-04-14 IL IL190865A patent/IL190865A0/en unknown
- 2008-05-20 MA MA30953A patent/MA29969B1/fr unknown
- 2008-05-23 EC EC2008008467A patent/ECSP088467A/es unknown
- 2008-06-30 NO NO20082938A patent/NO20082938L/no not_active Application Discontinuation
-
2010
- 2010-04-19 CL CL2010000387A patent/CL2010000387A1/es unknown
-
2012
- 2012-07-05 US US13/542,216 patent/US20120276200A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL1957074T3 (pl) | 2014-08-29 |
| EP2772257A1 (en) | 2014-09-03 |
| CA2627544A1 (en) | 2007-06-07 |
| MA29969B1 (fr) | 2008-11-03 |
| NO20082938L (no) | 2008-06-30 |
| ECSP088467A (es) | 2008-06-30 |
| NZ567550A (en) | 2011-08-26 |
| IL190865A0 (en) | 2008-11-03 |
| PT1957074E (pt) | 2014-06-25 |
| KR20080074143A (ko) | 2008-08-12 |
| AU2006320591A1 (en) | 2007-06-07 |
| EP1957074A2 (en) | 2008-08-20 |
| CL2010000387A1 (es) | 2010-08-06 |
| CN102670530A (zh) | 2012-09-19 |
| MY148529A (en) | 2013-04-30 |
| AU2006320591B2 (en) | 2010-06-03 |
| BRPI0619370A2 (pt) | 2011-09-27 |
| PE20070760A1 (es) | 2007-10-04 |
| RU2008126384A (ru) | 2010-01-10 |
| WO2007064719A3 (en) | 2007-08-16 |
| TW200730176A (en) | 2007-08-16 |
| ES2467162T3 (es) | 2014-06-12 |
| JP2009517481A (ja) | 2009-04-30 |
| US20120276200A1 (en) | 2012-11-01 |
| EP1957074B1 (en) | 2014-03-19 |
| WO2007064719A2 (en) | 2007-06-07 |
| CA2627544C (en) | 2015-07-07 |
| US20080293738A1 (en) | 2008-11-27 |
| RU2433826C2 (ru) | 2011-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA58498B1 (fr) | Agonistes hétérocycliques de glp-1 | |
| AR058293A1 (es) | Sales profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]pirimidin-5-carbonil)-2-metoxi-fenil]-3-(2,4-dicloro-fenil)-urea | |
| PE20090185A1 (es) | Formulaciones farmaceuticas que contienen un inhibidor sglt2 | |
| AR056873A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas | |
| AR063096A1 (es) | Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina | |
| CU20100200A7 (es) | Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias | |
| AR058780A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| PA8591701A1 (es) | Derivados de pirrolopirimidina | |
| SV2008001369A (es) | Benzimidazoles | |
| ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
| MA37405A1 (fr) | Composés hétérocyclyle | |
| NO20085060L (no) | Triazolpyrazinderivater anvendelige som anti-cancermidler | |
| ECSP088467A (es) | Formulaciones de quinolinonas | |
| AR036658A1 (es) | Formulacion de dosificacion oral de fundicion instantanea | |
| EP2168964A4 (en) | COUPLED AZAINDOL INDOL DERIVATIVES, MANUFACTURING METHOD AND APPLICATIONS THEREOF | |
| KR20210007066A (ko) | 퀴니딘 유도체를 유효성분으로 함유하는 항암보조제 | |
| AR077546A1 (es) | Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos | |
| AU2019351124A1 (en) | Inhibitors of VAP-1 | |
| Sharma et al. | Novel antiplasmodial compounds leveraged with multistage potency against the parasite plasmodium falciparum: in vitro and in vivo evaluations and pharmacokinetic studies | |
| AR056014A1 (es) | Compuesto 3-aminocarbazol, composicion farmaceutica que lo contiene y procedimiento para la preparacion del mismo | |
| ECSP23084907A (es) | Inhibidores heteroaromáticos bicíclicos de la klk5 | |
| CO2026000093A2 (es) | Composiciones farmacéuticas para inhibidores de la cinasa nek7 | |
| CN106164059A (zh) | 用天冬酰胺内肽酶（aep）抑制剂以及相关组合物对神经退行性疾病的治疗 | |
| JP2003055221A (ja) | 安定化された組成物 | |
| HRP20050815A2 (en) | 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |